ArticlePloS one2017
Assessing gastroenterologist and patient acceptance of biosimilars in ulcerative colitis and Crohn's disease across Germany.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 4 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Barriers and Enablers Affecting the Uptake of Biosimilar Medicines Viewed Through the Lens of Actor Network Theory: A Systematic Review.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2024Pooled it
- Patients' Perceptions of Biosimilars: A Systematic Review.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2023Pooled it
- Pooled it
- Factors Affecting Health Care Provider Knowledge and Acceptance of Biosimilar Medicines: A Systematic Review.Journal of managed care & specialty pharmacy · 2019Pooled it
- Understanding Patient Preferences on Inflammatory Bowel Disease Treatment Modalities and Outcomes: A Global Targeted Literature Review.Advances in therapy · 2026Review
- Uptake of biosimilars in China: a retrospective analysis of the case of trastuzumab from 2018 to 2023.Global health research and policy · 2024Article
- Treatment persistence and switching patterns of ABP 501 in European patients with inflammatory bowel disease.Therapeutic advances in gastroenterology · 2024Article
- Patient perspectives of successful adalimumab biosimilar transitioning in Crohn's disease: an interview study.European journal of hospital pharmacy : science and practice · 2022Article
- "Biosimilar, so it looks alike, but what does it mean?" A qualitative study of Danish patients' perceptions of biosimilars.Basic & clinical pharmacology & toxicology · 2022Article
- Factors associated with the uptake of biosimilars for breast cancer treatment from the perspectives of physicians and patients-Evidence from China.Frontiers in pharmacology · 2022Article
- Informing Patients about Biosimilar Medicines: The Role of European Patient Associations.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Patients' beliefs and behaviours are associated with perceptions of safety and concerns in a hypothetical biosimilar switch.Rheumatology international · 2021Article
- Lessons from International Experience with Biosimilar Implementation: An Application of the Diffusion of Innovations Model.Healthcare policy = Politiques de sante · 2020Article
- Patient Preferences for Biologic and Biosimilar Osteoporosis Treatments in Colombia.Patient preference and adherence · 2020Article
- Considerations for the US health-system pharmacist in a world of biosimilars.Drugs in context · 2020Article
- Biosimilars: concept, current status, and future perspectives in inflammatory bowel diseases.Intestinal research · 2020Review
- Nurses are Critical in Aiding Patients Transitioning to Biosimilars in Inflammatory Bowel Disease: Education and Communication Strategies.Journal of Crohn's & colitis · 2019Review
- Patient and physician preferences for attributes of biologic medications for severe asthma.Patient preference and adherence · 2019Article
- Real World Data on the Utilization Pattern and Safety Profile of Infliximab Originator Versus Biosimilars in Italy: A Multiregional Study.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2018Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study examined gastroenterologists' motivation for prescribing biosimilars, assessed their treatment preferences in relation to prescribing behaviour, and explored patient attitudes to biosimilars.
methodsData were taken from the Adelphi Real World Biosimilars Programme, a real-world, cross-sectional study undertaken in 2015-2016 with German gastroenterologists and patients with ulcerative colitis or Crohn's disease. Gastroenterologists provided data on their prescribing behaviour and attitudes towards biosimilars, and invited the next eight eligible consecutive consulting patients to complete a detailed questionnaire. For analysis, gastroenterologists were split into 'Investigative', 'Conservative', and 'Other' groups.
resultsOverall, 25 gastroenterologists and 136 patients participated. Biosimilars accounted for <15% of all biologic therapies and >80% of gastroenterologists would prescribe a bio-originator rather than biosimilar as 1st line therapy if unrestricted. Patients showed some reluctance to accept biosimilars, although of those receiving biosimilars, 79% were satisfied with the current treatment of their condition, and 69% were satisfied with the control of symptoms. Although at least 35% of patients in each analysis group reported no concerns when starting treatment with a bio-originator or biosimilar, 41% of previously biologic-naïve patients prescribed a biosimilar indicated potential side effects and potential long-term problems, and 24% not knowing enough about the drug, as concerns.
conclusionResults demonstrate that there is reluctance from patients to accept biosimilars and the need to further educate patients who are unsure to allow them to be involved in decision making, highlighting the importance of patient and physician communication. There remains a need for further research into non-clinical switching and the long term impact of prescribing biosimilars.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.